Ken Krause
Analyst · Sidoti & Company. Mr. Marshall, please go ahead
Thanks, Nish and good morning, everyone. Before I begin the fourth quarter financial review, I’d like to start with a few highlights related to our full year performance. Full year total revenue increase 3% in constant currency finishing in the low to mid-single digit range that we communicated to you throughout 2017. We saw gross margin improvement across many of our core products in 2017 driving full year core product margin expansion of 50 basis points excluding the impact of Globe. Reported SG&A declined $8 million for the full year but on an organic constant currency basis SG&A declined $16 million for the year, nicely exceeding our previously communicated cost savings goal of $10 million for 2017. For the full year adjusted operating margin was 16.1%, which includes approximately 40 basis points of strategic transaction costs incurred to pursue growth through acquisitions. The full year margin is a record for MSA and 130 basis points up from 2016. Going further back to 2015, we’ve expanded adjusted operating margin by 400 basis points over two years. We converted more than 100% of net income to free cash flow again in 2017. We made strong progress collecting insurance receivables and managed working capital to a level necessary to support our fourth quarter and expected 2018 growth. Now I’d like to take some time to walk you through our quarterly financial results. Total revenue increased 14% in the quarter in constant currency terms or 6% on an organic basis when we exclude the impact of Globe. Solid gains in every core product line supported our quarterly growth and as Nish mentioned our order pace strengthened considerably in the fourth quarter on both the sequential and year-over-year basis. Gross profit was down about 200 basis points in the quarter mostly related to Globe and the related amortization associated with the acquisition related accounting. While Globe is dilutive to gross profit due to product mix it is accretive to EBITDA margins EPS and cash flow. SG&A expense was $75 million in the quarter, in organic constant currency terms SG&A declined $5 million in the quarter and $16 million for the full year. We’ve made good progress at realizing returns on our restructuring investments and driving a cost conscious culture. With that, I just like to remind you that we oftentimes see an increase in SG&A in Q1 related to accounting for stock compensation related expenses. As you probably recall, we reported a $30 million pretax charge in the second quarter of 2017 related to resolve cumulative trauma product liability settlements as well as estimated indemnity for all remaining asserted claims. As Bill mentioned, we continue to work with our evaluation consultant and legal counsel in the quarter to complete our annual process of assessing unasserted or incurred but not reported or otherwise known as IBNR claims. In the past we were unable to quantify a liability associated with IBNR claims. However, our defense strategy continue to evolve over the past couple of years and that has produced a more stable claims experience, improved visibility and predictability of claims composition amongst other things that enabled us to make a reasonable estimate of the IBNR liability. As a result, we increased our product liability reserve for IBNR cumulative trauma product liability claims in the fourth quarter by $111 million, which reflects our estimated liability through the year 2060. The corresponding charge for the income statement which is a non-cash charge was $93 million, which primarily reflects the increase to the IBNR reserve net of what we expect to receive from insurance for those claims. I think it’s important to note our reserve does not include an estimate for future defense costs and it is not recorded at present value. Our product liability reserve now approximates $180 million, which includes an estimate for both asserted and IBNR claims. Understanding that it is important to remember the other side of the equation, which is the insurance receivable. At year end we had insurance receivables of about $212 million and approximately $80 million of that balance reflects notes receivables. So on a net basis our balance sheet has a net asset of approximately $30 million associated with cumulative trauma product liability related matters at December 31. GAAP operating loss was $31 million in the quarter reflecting the impact of the non-cash product liability accrual I just mentioned. Excluding FX, restructuring and product liability expense adjusted operating margin was our highest quarterly result ever at 18.6% improving 240 basis points from a year ago. We incurred about $1 million of costs associated with Globe’s integration in the quarter and that negatively impacted operating margins by about 30 basis points. From a reporting standpoint, we will adopt the new accounting standard for pension accounting in 2018, which indicates that all components of net periodic benefit cost except for service costs should be reported outside of operating income. This change has the ability to reduce operating margins by about 20 to 30 basis points but it is neutral to earnings per share. We will begin reporting under the new methodology in the first quarter of 2018 and will adjust the 2017 results to conform with this new basis of presentation when we report in the first quarter. As I mentioned on the third quarter call, we have started to analyze adjusted EBITDA as a profitability metric to neutralize the impact of purchase accounting from the M&A investments we have made over the past several years. Adjusted EBITDA excludes strategic transaction costs, product liability, restructuring and FX gains and losses. Quarterly adjusted EBITDA increased 29% to $75 million or just under 22% of sales compared to 19.7% a year ago. For the full year this measure was $234 million or 19.5% of sales compared to 18% in 2016. Our GAAP effective tax rate was 9.5% for the full year of 2017, which includes a $20 million one-time charge related to U.S. tax reform associated with our expected cash repatriation efforts as well as the re-measurement of deferred tax assets and liabilities under the new lower U.S. rate. Our full year GAAP rate includes the impact of the product liability accrual, windfall benefit associated with stock compensation and reversal of exit taxes, which are more than offsetting the charge associated with the tax reform. On an adjusted normalized basis our ETR is 26.6% for 2017 compared to about 34% in 2016. I’d like to take a moment to discuss the anticipated impact of U.S. tax reform. As you know our profitability mix is heavily weighted toward the U.S. in our recent acquisition of U.S. based Globe makes the trend even more pronounced. As a result, we expect tax reform to have a significant impact on our effective tax rate with historically over 70% of our profitability generated in the U.S. coupled with our recent acquisition in the U.S. We expect a lift in earnings in 2018 from the recent tax reform. We will provide more updates as we progress throughout 2018. Another benefit of tax reform is the significant cash balances we are holding outside of the U.S. We are actively working to repatriate between $75 million and $100 million of foreign cash throughout 2018 and plan to start bringing cash back to the U.S. in the first quarter. Higher cash flow from the lower tax rate and cash repatriation provide support to execute our established capital allocation strategy. Focusing back on the quarterly results, GAAP net loss was $33 million in the quarter, which reflects the product liability accrual and tax expense associated with tax reform. Adjusted earnings increased 69% to $51 million or $1.31 per share compared to $0.78 per share a year ago. For the full year adjusted earnings were $141 million or $3.65 per share reflecting a 34% increase from a year ago on the 3% increase in revenue. Looking back even further to 2015, adjusted EPS was $2.52 at that time. So over the past two years, we’ve continued to execute on value creation programs and we’ve invested heavily in strategic acquisitions. Accordingly, about a quarter of our earnings expansion since 2015 is related to acquisitions, while the remainder reflects organic activities associated with the recovery of core industrial products, cost savings and tax planning. For the full year, we converted over 100% of net income to cash flow and we deployed $216 million for the acquisition of Globe, $53 million for dividends and $17 million for share repurchases primarily related to offsetting dilution. Our debt to EBITDA at the end of the fourth quarter was 2 times compared to 1.8 time at the same time a year ago, despite having executed the Globe acquisition for just about $216 million. I’m pleased with the strong finish in 2017 and the progress we have made in improving profitability and cash flow over the past several years. As we look 2018 we are planning for mid single digit organic revenue growth for the full year up from an organic decline of 1% in 2017. And we’ll continue to focus on driving earnings growth at a faster rate in sales and turning these profits in the cash flow that can be used to continue to fund our capital deployment activities. With the benefit of U.S. tax reform and a broad-based strength in many of our end markets and geographies there are a number of tailwinds that would drive value for all stakeholders in 2018 and beyond. We look forward to discussing our value creation strategies with you at our upcoming Investor Day, which we are hosting at the New York Stock Exchange on March 12. We hope to see you there, but for those that cannot attend, the live webcast and replay of the event will be available on our Investor Relations website. With that, I’ll turn the call over to Bill for some concluding commentary. Bill?